About Cysteine protease ATG4D
Cysteine protease ATG4D (ATG4D) is a protein
from Homo sapiens identified by UniProt accession
Q86TL0, 474 residues long.
MolForge cross-references it against 0 known binders and
72 disease associations.
Target properties
| Protein name | Cysteine protease ATG4D |
| UniProt accession | Q86TL0 |
| Gene | ATG4D |
| Organism | Homo sapiens |
| Length | 474 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (72)
Diseases linked to this target (Open Targets).
- muscle strain · score 0.25
- sprain · score 0.25
- dislocation · score 0.25
- total cholesterol measurement · score 0.21
- low density lipoprotein cholesterol measurement · score 0.20
- Neurodevelopmental disorder · score 0.19
- breast adenocarcinoma · score 0.18
- neutrophil count · score 0.10
- neutrophil percentage of leukocytes · score 0.09
- platelet count · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86TL0-F1 | alphafold | PREDICTED | 77.41 | — |
Amino-acid sequence (474 residues)
MNSVSPAAAQ YRSSSPEDAR RRPEARRPRG PRGPDPNGLG PSGASGPALG SPGAGPSEPD EVDKFKAKFL TAWNNVKYGW VVKSRTSFSK ISSIHLCGRR YRFEGEGDIQ RFQRDFVSRL WLTYRRDFPP LPGGCLTSDC GWGCMLRSGQ MMLAQGLLLH FLPRDWTWAE GMGLGPPELS GSASPSRYHG PARWMPPRWA QGAPELEQER RHRQIVSWFA DHPRAPFGLH RLVELGQSSG KKAGDWYGPS LVAHILRKAV ESCSDVTRLV VYVSQDCTVY KADVARLVAR PDPTAEWKSV VILVPVRLGG ETLNPVYVPC VKELLRCELC LGIMGGKPRH SLYFIGYQDD FLLYLDPHYC QPTVDVSQAD FPLESFHCTS PRKMAFAKMD PSCTVGFYAG DRKEFETLCS ELTRVLSSSS ATERYPMFTL AEGHAQDHSL DDLCSQLAQP TLRLPRTGRL LRAKRPSSED FVFL
Explore Cysteine protease ATG4D with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets